DrugRepV|Encyclopedia for antivirals

Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_7091

Chemical Information
Antiviral agent ID DrugRepV_7091
Antiviral agent name NITD008
IUPAC Name (2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)oxolane-3,4-diol
SMILES (canonical) C#CC1(C(C(OC1N2C=CC3=C2N=CN=C3N)CO)O)O
SMILES (isomeric) C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O
Molecular Formula C13H14N4O4
Molecular Weight (g/mol) 290.279

InChl InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1

Synonyms 7-Deaza-2'-C-ethynyladenosine | 7-(2-C-Ethynyl-?-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Structural Information

Clinical Information
Category Antiviral
Biological Information
Secondary Indication Yellow fever virus (YFV) NA 17D vaccine strain
Secondary Indication (Approaches) Experimental
Secondary Indication (Methods) in-vitro
Secondary Indication (Model system) [cell lines/ animal models] Vero
Secondary Indication (Mode of viral infection) Adsorption
Secondary Indication (Viral titer) 0.1 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Time of drug delivery) During inoculation
Secondary Indication (Duration of drug delivery) 48 hours
Secondary Indication (Drug concentration) 6 μM
Secondary Indication (Cell based assay) Plaque assay
Secondary Indication (Change) Decrease
Secondary Indication (Type of Inhibition) EC50 [ 50 % ]
Reference Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminaraya.An adenosine nucleoside inhibitor of dengue virus..Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9. doi: 10.1073/pnas.0907010106. Epub 2009 Nov 16 PMID:19918064
Comment A triphosphate form of NITD008 directly inhibits the RNA-dependent RNA polymerase activity of DENV, indicating that the compound functions as a chain terminator during viral RNA synthesis. NITD008 has good in vivo pharmacokinetic properties and is biologically available through oral administration.

Copyright © 2019. CSIR-Institute of Microbial Technology, Chandigarh, INDIA.

Chemical Information
Antiviral agent ID	DrugRepV_7091
Antiviral agent name	NITD008
IUPAC Name	(2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)oxolane-3,4-diol
SMILES (canonical)	C#CC1(C(C(OC1N2C=CC3=C2N=CN=C3N)CO)O)O
SMILES (isomeric)	C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O
Molecular Formula	C13H14N4O4
Molecular Weight (g/mol)	290.279
InChl	InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1
Synonyms	7-Deaza-2'-C-ethynyladenosine \| 7-(2-C-Ethynyl-?-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Structural Information

Clinical Information
Category	Antiviral
Biological Information
Secondary Indication	Yellow fever virus (YFV) NA 17D vaccine strain
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	in-vitro
Secondary Indication (Model system) [cell lines/ animal models]	Vero
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	0.1 MOI
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	During inoculation
Secondary Indication (Duration of drug delivery)	48 hours
Secondary Indication (Drug concentration)	6 μM
Secondary Indication (Cell based assay)	Plaque assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Reference	Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminaraya.An adenosine nucleoside inhibitor of dengue virus..Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9. doi: 10.1073/pnas.0907010106. Epub 2009 Nov 16 PMID:19918064
Comment	A triphosphate form of NITD008 directly inhibits the RNA-dependent RNA polymerase activity of DENV, indicating that the compound functions as a chain terminator during viral RNA synthesis. NITD008 has good in vivo pharmacokinetic properties and is biologically available through oral administration.